Gemcitabine and irinotecan in patients with previously treated carcinoma of unknown primary site: A Minnie Pearl Cancer Research Network phase II trial

Doss, H. H.; Hainsworth, John D.; Spigel, David R.; Kommor, M.; Zakem, Michael H.; Raefsky, Eric; Litchy, Sharlene; Greco, F. Anthony

doi:10.1200/jco.2004.22.90140.4167

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequently, the combination of gemcitabine, carboplatin, and paclitaxel in the fourth study in 120 patients was found to be active, to be associated with acceptable toxicity, and to result in survival similar to our previous three taxane-based regimens for these patients [4]. Recent clinical experience with irinotecan (Campostar ® ; Pfizer Pharmaceuticals; New York, NY), both alone and combined with gemcitabine [5], has been encouraging and relatively well tolerated as second-line therapy.…”

Section: Introductionmentioning

confidence: 76%

Carcinoma of Unknown Primary Site: Sequential Treatment with Paclitaxel/Carboplatin/Etoposide and Gemcitabine/Irinotecan: A Minnie Pearl Cancer Research Network Phase II Trial

et al. 2004

View full text Add to dashboard Cite

Patients and Methods. One hundred thirty-two patients were treated with sequential combination chemotherapy for a maximum of six cycles. All patients had relatively poor prognostic features. Fifty-nine patients had well-differentiated adenocarcinoma, 73 patients had poorly differentiated carcinoma, and 121 patients had performance status scores of 0 or 1.Results. Thirty-three (30%) of 111 assessable patients (95% confidence interval 27%-33%) had objective responses to treatment (26 partial responses, seven complete responses). The combination of gemcitabine and irinotecan was associated with significantly less toxicity than the triple-drug regimen and improved the responses in several patients (10%). The response rates were similar in the two major histologic tumor types, but were lower for patients with liver-dominant tumors (13%) and higher for patients with lymph-node-dominant tumors (50%). The median progression-free survival time, median survival time, and actuarial survival rates at 1 and 2 years were 5.7 months, 9.1 months, 35%, and 16%, respectively.Conclusions. Sequential combination chemotherapy with paclitaxel/carboplatin/oral etoposide and gemcitabine/irinotecan is an active treatment for patients with carcinoma of unknown primary site, but overall toxicities are greater than those seen with other combinations of new drugs and survival appears similar to that observed in 264 other patients treated in our four previous phase II trials. A better understanding of the biology of these heterogeneous tumors will likely lead to improved therapy for these patients. The Oncologist

show abstract

Section: Introductionmentioning

confidence: 76%